RxDoctor Payments Data

Varun Avula

Cardiovascular Disease · Butler, PANPI 1356754949

Payments from drug & device makers

$36,188in general payments, 2019–2025

Across 533 payments — averaging $67.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • Shockwave Medical, Inc$8K
  • Boston Scientific$4K
  • Edwards Lifesciences$3K
  • Abiomed$2K
  • Inari Medical, Inc.$1K
  • plus $5K from 35 others

What the payments were for

  • Speaking & faculty fees$6,60018%
  • Grants$1,1053%
  • Travel & lodging$9,14525%
  • Food & beverage$19,26953%
  • Education$690%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,188 in reported general payments places this provider in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$71,608
Medicare patients
292
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArcalystRilonacept13$298,806
EntrestoSacubitril/Valsartan100$89,270
EliquisApixaban95$74,488
XareltoRivaroxaban63$49,107
BrilintaTicagrelor33$31,905
Repatha SureclickEvolocumab45$29,299
JardianceEmpagliflozin12$12,688
FarxigaDapagliflozin Propanediol13$10,274
Ranolazine ErRanolazine104$5,944
Rosuvastatin Calcium169$3,143
Metoprolol Succinate232$3,080
Isosorbide Mononitrate ErIsosorbide Mononitrate88$1,169
Atorvastatin Calcium86$970
Potassium Chloride26$792
Bumetanide18$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kiniksa Pharmaceuticals International, PLCArcalyst$18$298,80613 claims
NovartisEntresto$140$89,270100 claims
PfizerEliquis$302$74,48895 claims
Johnson & JohnsonXarelto$160$49,10763 claims
AstraZenecaBrilinta, Farxiga$446$42,17946 claims
Boehringer IngelheimJardiance$204$12,68812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →